Weekly Recro Pharma, Inc. (NASDAQ:REPH) Ratings

May 16, 2018 - By Mary Kidd

Recro Pharma, Inc. (NASDAQ:REPH) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.5. That’s change of 0.15, from 2017Q3’s 1.65. 4 investors sold all, 14 reduced holdings as Recro Pharma, Inc. ratio dived. 20 rose holdings while 7 funds took holdings. Funds hold 9.57 million shares thus 0.59% less from 2017Q3’s 9.63 million shares.
Parallax Volatility Advisers L P owns 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 2,058 shs. State Common Retirement Fund holds 0% of its capital in Recro Pharma, Inc. (NASDAQ:REPH) for 6,800 shs. Natl Bank Of Montreal Can accumulated 4,564 shs. Bb&T reported 0.01% of its capital in Recro Pharma, Inc. (NASDAQ:REPH). Essex Inv Mgmt Ltd holds 0.11% or 92,565 shs in its capital. Bnp Paribas Arbitrage stated it has 0% of its capital in Recro Pharma, Inc. (NASDAQ:REPH). Morgan Stanley reported 0% of its capital in Recro Pharma, Inc. (NASDAQ:REPH). Ameritas Invest Prtn holds 0% or 1,196 shs in its capital. 1 are owned by Royal Fincl Bank Of Canada. Jpmorgan Chase & has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 31,673 shs. Barclays Public Limited Company holds 0% in Recro Pharma, Inc. (NASDAQ:REPH) or 2,610 shs. Schwab Charles Mgmt reported 81,269 shs. Advisory Ntwk Ltd Liability Com reported 1,110 shs. Macquarie Group Limited stated it has 0% in Recro Pharma, Inc. (NASDAQ:REPH). 10,650 were accumulated by Janney Montgomery Scott Ltd Liability.

Recro Pharma, Inc. registered $3.53 million net activity with 0 insider purchases and 7 selling transactions since December 12, 2017. 12,964 shs were sold by SCP Vitalife Partners (Israel) II – L.P., worth $115,139. On Tuesday, December 12 Shares for $919,128 were sold by Broadfin Healthcare Master Fund Ltd. On Friday, March 9 $78,347 worth of stock was sold by Berelowitz Michael.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

In total 3 analysts cover Recro Pharma (NASDAQ:REPH). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 4 are the (NASDAQ:REPH)’s analyst reports since February 13, 2018 according to StockzIntelligence Inc. On Wednesday, February 28 Piper Jaffray maintained Recro Pharma, Inc. (NASDAQ:REPH) with “Buy” rating. On Thursday, April 19 Berenberg initiated the shares of REPH in report with “Buy” rating. On Tuesday, February 13 Oppenheimer initiated Recro Pharma, Inc. (NASDAQ:REPH) with “Buy” rating. On Thursday, May 10 the company was maintained by Oppenheimer. Listed here are Recro Pharma, Inc. (NASDAQ:REPH) PTs and latest ratings.

10/05/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0000 Maintain
19/04/2018 Broker: Berenberg Rating: Buy New Target: $21.2500 Initiate
28/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $12.0 Maintain
13/02/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Initiate

REPH is touching $10.83 during the last trading session, after increased 0.74%.Recro Pharma, Inc. has volume of 132,650 shares. Since May 16, 2017 REPH has risen 37.47% and is uptrending. REPH outperformed by 25.92% the S&P 500.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States.The company has $222.10 million market cap. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain.Last it reported negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

For more Recro Pharma, Inc. (NASDAQ:REPH) news announced briefly go to: Seekingalpha.com, Nasdaq.com, Seekingalpha.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “How To Use Probabilities In Investing: Open Sources” announced on May 11, 2018, “Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting” on April 30, 2018, “Recro Pharma’s (REPH) CEO Gerri Henwood on Q1 2018 Results – Earnings Call Transcript” with a publish date: May 09, 2018, “Berenberg Starts Recro Pharma (REPH) at Buy” and the last “Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam” with publication date: May 07, 2018.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: